| Literature DB >> 30545210 |
Chih-Chang Chang1,2, Wen-Cheng Huang1,2, Jau-Ching Wu1,2, Praveen V Mummaneni3.
Abstract
Cervical disc arthroplasty (CDA), or total disc replacement, has emerged as an option in the past two decades for the management of 1- and 2-level cervical disc herniation and spondylosis causing radiculopathy, myelopathy, or both. Multiple prospective randomized controlled trials have demonstrated CDA to be as safe and effective as anterior cervical discectomy and fusion, which has been the standard of care for decades. Moreover, CDA successfully preserved segmental mobility in the majority of surgical levels for 5-10 years. Although CDA has been suggested to have long-term efficacy for the reduction of adjacent segment disease in some studies, more data are needed on this topic. Surgery for CDA is more demanding for decompression, because indirect decompression by placement of a tall bone graft is not possible in CDA. The artificial discs should be properly sized, centered, and installed to allow movement of the vertebrae, and are commonly 6 mm high or less in most patients. The key to successful CDA surgery includes strict patient selection, generous decompression of the neural elements, accurate sizing of the device, and appropriately centered implant placement.Entities:
Keywords: Adjacent segment disease; Anterior cervical discectomy and fusion; Cervical disc arthroplasty; Myelopathy; Radiculopathy; Total disc replacement
Year: 2018 PMID: 30545210 PMCID: PMC6347355 DOI: 10.14245/ns.1836186.093
Source DB: PubMed Journal: Neurospine ISSN: 2586-6591
Fig. 1.Preoperative magnetic resonance images (sagittal and axial view over C5–6, A and B), computed tomography (axial view over C5–6 and sagittal, C and D).
Fig. 2.Preoperative lateral dynamic radiographs: flexion (A) and extension (B).
Fig. 3.Immediate postoperative radiographs: anteriorposterior (A) and lateral (B).
Fig. 4.Postoperative 6 months lateral dynamic radiographs: flexion (A) and extension (B).
Summary of FDA-IDE trials
| Device | Author | Year | Manufacturer | Study type | Level | Population | Follow-up (yr) | ROM | Secondary surgery | High grade HO[ |
|---|---|---|---|---|---|---|---|---|---|---|
| Bryan | Heller [ | 2009 | Medtronic | FDA-IDE prospective randomized Controlled trial | 1 | 242 Bryan vs. 221 ACDF | 2 | 8.4° | Index level: 2.5% vs. 3.6% | N/A |
| Bryan | Sasso [ | 2017 | Medtronic | FDA-IDE prospective randomized Controlled trial | 1 | 24 Bryan vs. 23 ACDF | 10 | N/A | Index level: 4.5% vs. 0% | N/A |
| Adjacent level: 4.5% vs. 32% | ||||||||||
| Bryan Kineflex|C | Coric [ | 2013 | Medtronic | FDA-IDE prospective randomized Controlled trial | 1 | 41 CDA vs. 33 ACDF | 4 | 8.6° | Index level: 2.4% vs. 0% | 17% |
| Spinal Motion | Adjacent level: 4.9% vs. 3% | |||||||||
| Kineflex|C | Coric [ | 2018 | Spinal Motion | FDA-IDE prospective randomized Controlled trial | 1 | 136 Kineflex|C vs. 133 ACDF | 5 | 10.6° | 8.2% vs. 8.3% | 26.1% |
| Prestige ST | Mummaneni [ | 2007 | Medtronic | FDA-IDE prospective randomized Controlled trial | 1 | 276 Prestige ST vs. 265 ACDF | 2 | 7.59° | 1.8% vs. 5.2% | N/A |
| Prestige ST | Burkus [ | 2014 | Medtronic | FDA-IDE | 1 | 276 Prestige vs. 265 ACDF | 7 | 6.75° | Index level: 4.8% vs. 13.7% | 10% |
| Prospective randomized controlled trial | Adjacent level: 4.6% vs. 11.9 | |||||||||
| Prestige LP | Gornet [ | 2015 | Medtronic | FDA-IDE prospective nonrandomized trial | 1 | 280 Prestige LP | 2 | 7.5° | 5% | 9.6% |
| Prestige LP | Gornet [ | 2017 | Medtronic | FDA-IDE prospective randomized Controlled trial | 2 | 209 Prestige LP vs. 188 ACDF | 2 | 6.92°, 6.85° | Index level: 2.4% vs. 8% | 16.1%–19.7% |
| Adjacent level: 2.4% vs. 3.2% | ||||||||||
| Prestige LP | Lanman [ | 2017 | Medtronic | FDA-IDE prospective randomized Controlled trial | 2 | 209 Prestige LP vs. 188 ACDF | 7 | Around 6.5°[ | Index level: 4.2% vs. 14.7% | 32.5%–34.4% |
| Adjacent level: 6.5% vs. 12.5% | ||||||||||
| Mobi-C | Davis [ | 2013 | LDR Medical | FDA-IDE prospective randomized Controlled trial | 2 | 225 Mobi-C vs. 105 ACDF | 2 | 10.1°, 8.3° | 3.1% vs. 11.4% | 10.1%–11.5% |
| Mobi-C | Radcliff [ | 2016 | Zimmer biomet | FDA-IDE prospective randomized Controlled trial | 2 | 225 Mobi-C vs. 105 ACDF | 7 | 10.2° | Index level: 4.4% vs. 16.2% | N/A |
| Adjacent level: 3.7% vs. 13.6% | ||||||||||
| ProDisc-C | Murrey [ | 2009 | Synthes | FDA-IDE prospective randomized Controlled trial | 1 | 103 ProDisc-C vs. 106 ACDF | 2 | 9.36° | 1.9% vs. 8.5% | N/A |
| ProDisc-C | Loumeau [ | 2016 | Synthes | FDA-IDE prospective randomized Controlled trial | 1 | 41 ProDisc-C vs. 22 ACDF | 7 | > 7° | 0% vs. 27.3% | 56% |
FDA-IDE, U. S. Food and Drug Administration-Investigational Device Exemption; ROM, range of motion; HO, heterotrophic ossification; ACDF, anterior cervical discectomy and fusion; CDA, cervical disc arthroplasty; N/A, not available.
Incidence of HO differed from detection method.
Approximation from figure.
Other studies for different clinical scenario
| Cervical disc | Author | Year | Study type | Treatment | Followup (mo) | Population | Result |
|---|---|---|---|---|---|---|---|
| Bryan | Tu [ | 2011 | Retrospective | 1- and 2-level | 12 | 36 Bryan | The HO had an incidence at 48.1% per level, and did not affect clinical outcomes |
| Bryan | Tu [ | 2012 | Retrospective | 1- and 2-level | 24 | 75 Patient | Shell kyphosis and inadequate endplate coverage have adverse effects on the formation of HO after CDA |
| Bryan | Wu [ | 2012 | Retrospective | 1-Level | 45.5 | 16 Soft disc herniation | Soft disc herniation and spondylosis had similar clinical outcomes. However, the spondylosis group had more HO significantly less HO. |
| 24 Spondylosis | |||||||
| Bryan | Wu [ | 2012 | Retrospective control | 1- and 2-level | 46.2 | 42 1-level CD A | There were more HO in the 2-level CDA patients than the 1-level, although the clinical outcomes were similar |
| 28 2-level CD A | |||||||
| Bryan | Wu [ | 2013 | Retrospective | Multilevel | 38.3 | 36 1-level CD A | Patients with multi-level CDA had similar clinical outcomes than that with single-level CDA |
| 27 2-level CD A | |||||||
| 23 2-level CDA+1 level ACDF | |||||||
| Bryan | Fay [ | 2014 | Retrospective control | 1- and 2-level | 36.4 | 72 Myelopathy | Patients with cervical myelopathy had similar outcomes than that with radiculopathy after CDA. |
| Prestige LP | 53 Radiculopathy | ||||||
| Bryan | Fay [ | 2014 | Retrospective control | 2-Level | 40 | 37 Bryan | For patients with 2-level cervical disc herniation and spondylosis, CDA could preserve segmental mobility and yielded similar outcomes than ACDF. |
| 40 ACDF | |||||||
| Bryan | Tu [ | 2015 | Retrospective | 1- and 2-level | 38.7 | 53 CD A with NS AID use | Postoperative NSAIDs use could be associated with less HO |
| 22 CDA without NSAID use | |||||||
| Bryan | Chang [ | 2015 | Retrospective age- and sex- matched control | 1- and 2-level | 29.6 | Traumatic disc herniation | In patients with traumatic cervical disc herniation, CDA yielded similar outcomes as ACDF |
| Prestige LP | 15 CDA | ||||||
| 15 ACDF | |||||||
| Bryan | Chang [ | 2016 | Retrospective control | 1-Level | 60 | 11C3-4 CDA | There were more HOs after CDA at C3-4 |
| Prestige LP | 77 non-C3-4 CDA | ||||||
| ProDisc-C | |||||||
| Prestige LP | Chang [ | 2016 | Retrospective | 3-Level | 18 | Cervical spondylotic myelopathy with OPLL 15 hybrid ACCF (for OPLL)+CDA (for disc) | Hybrid CDA has satisfactory clinical outcome in patient of CSM with OPLL |
| ProDisc-C | |||||||
| Bryan | Chang [ | 2016 | Retrospective control | 1-Level | 30 | Degenerative disc disease with IISI: 22 IISI, 69 without IIS I | CDA was similarly effective for patients with or without IIS I |
| Prestige LP | |||||||
| ProDisc-C | |||||||
| Bryan | Chang [ | 2017 | Retrospective control | 3-Level | 28.4 | Congenital cervical stenosis 20 hybrid CDA (2-level CDA+1-level ACDF), 17 3-level ACDF | CDA was as effective as ACDF for patients with congenital cervical stenosis. |
| Prestige LP | |||||||
| ProDisc-C | |||||||
| Nova | |||||||
| Prestige LP | Chang [ | 2017 | Retrospective | 1-Level | 27.7 | 50 Prestige | Segmental mobility and overall cervical alignment had no influences on the clinical outcomes after CDA. However, patients with increased segmental mobility had less HO formation |
HO, heterotrophic ossification; CDA, cervical disc arthroplasty; ACDF, anterior cervical discectomy and fusion; NSAID, nonsteroidal anti-inflammatory drugs; OPLL, ossification of the posterior longitudinal ligament; IISI, increased intramedullary signal intensity.